Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US

Published: Monday, July 16, 2012
Last Updated: Monday, July 16, 2012
Bookmark and Share
CLIA laboratory to provide guidance for the use of Erbitux®.

Lab21 Limited has announced that its CLIA laboratory in Greenville, South Carolina, has been named as one of nine laboratories in the US to offer the first FDA approved companion diagnostic test to provide guidance for the use of Erbitux® (cetuximab).

Recent FDA approval of the Qiagen therascreen KRAS test, allows it to be used to determine whether patients with metastatic colorectal cancer are suitable for treatment with Erbitux.

The test has been routinely used in Europe since 2008 and is the first KRAS assay to secure FDA approval.

The availability of this test gives healthcare providers an FDA approved test which provides fast, consistent and reliable data to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-targeted inhibitor therapy.

Lab21 has been providing a KRAS analysis service using the assay from its CPA Accredited laboratory in Cambridge, UK for both Amgen and Merck Serono since 2008, and has performed in excess of 6000 tests during this time, including patient samples originating in a number of countries in Europe and the Middle East.

Michael Bolick, President of Lab21 Inc., commented: “Lab21 Inc. is delighted to have launched the therascreen KRAS assay as part of our initial portfolio of molecular diagnostic tests. As the only laboratory in Qiagen’s launch group based in the South-eastern region of the US market, Lab21 is well positioned to be the first provider of this valuable service to the regional cancer community.”

Mike Annable, Divisional Director - Clinical Laboratory, added, “Lab21 has significant clinical experience with the therascreen KRAS assay having been one of the first commercial labs to provide this validated assay in the UK. We have been able to leverage this experience during the laboratory validation of the assay for the US market and we are pleased that Erbitux patients can benefit from this experience.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 Partners with Top 10 IVD Player
Agreement to develop, manufacture and distribute new Aspergillus molecular assay.
Wednesday, April 11, 2012
Lab21 Announces Appointment of Industry Expert Fraser Logue
Dr Logue joins Lab21 team as Group Director of Quality, Regulatory Affairs & Operations Excellence.
Tuesday, February 21, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos